MedPath

Virtual Reality Devices As an Adjunct to Usual Care for Patients with Sickle Cell Disease Experiencing Vaso-Occlusive Crises

Not Applicable
Recruiting
Conditions
Vaso-occlusive Pain Episode in Sickle Cell Disease
Sickle Cell Disease
Acute Pain
Interventions
Device: Virtual Reality Headset and Hand-Held Controllers
Other: Blindfolding and Noise Cancelling
Registration Number
NCT06184126
Lead Sponsor
University of Maryland, Baltimore
Brief Summary

This study aims to evaluate the use of virtual reality as an adjunct to standard care for patients with sickle cell disease experiencing vaso-occlusive crises.

Detailed Description

A prospective, non-blinded, non-randomized trial will be conducted at the Adult Emergency Department at the University of Maryland Medical Center and Adult Urgent Care Center, which is managed by the Department of Emergency Medicine, located in Baltimore, Maryland.

Patients meeting eligibility criteria and who have signed the research informed consent will be enrolled in this study. Subject data collected will include demographic information, symptoms of the current illness and physical exam findings.

Upon enrollment into the study, a study team member will interview the patient to collect data needed to complete the Case Report Form. Patients assigned to one of the two virtual reality study groups will be directed by research coordinators who can help with equipment as needed throughout the session. The virtual reality device will be limited to a maximum of 2 hours of use. Assessments will be made at 4 different timepoints: 1) Immediately before the intervention, 2) at the 1-hour mark of the intervention, 3) immediately after the intervention, and 4) 1 hour after the intervention. During these assessments, patients will rate their pain intensity using a 0-10 numerical scale. Additionally, at each assessment, patients will be asked to state the change in pain that has taken place since the last measurement. This measurement will be performed without informing the patient of their previously recorded pain scores.

Data will also be recorded regarding the patient's 1) comfort of the device, 2) disposition (discharged home vs observation/admission status), 3) total length of treatment time in the ED (measured as time to initiation of any treatment to the time of final disposition), and 4) total amount of opioids administered while under the care of the emergency department clinicians, converted into morphine milligram equivalents. Each patient will complete a questionnaire at the conclusion of the session regarding their perceived impact of the intervention, ease of use, and likelihood to reuse the intervention.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Adult (age > 18 years) emergency department patient
  • History of sickle cell disease
  • Presenting to the emergency department due to acute pain related to sickle cell disease thought to be due to vaso-occlusive crisis
Exclusion Criteria
  • Prior enrollment in this study
  • Presenting with a chief complaint suggestive of a complicated crisis (such as concern for acute chest syndrome, splenic sequestration, hepatic sequestration, pulmonary embolism) as determined by the clinical care provider
  • Not being treated with intravenous opioids for the vaso-occlusive crisis
  • Patients who lack the capacity to provide informed consent
  • Medical history of seizures or known intolerance to virtual reality
  • Disabilities like vision and hearing defects etc. that preclude the use of a head mounted virtual reality device.
  • Known to be pregnant
  • Incarcerated at the time of evaluation
  • Over the age of 89 years old

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Active Immersive Virtual RealityVirtual Reality Headset and Hand-Held ControllersPatient with sickle cell disease experiencing acute vaso-occlusive crisis randomized to this arm will participate in an active immersive application on the virtual reality headset with hand-held controllers. The active immersive application will allow the user to interact directly with the application and move through the virtual environment .The patient will be able to use the active immersive application on the device for a maximum of two hours.
Blindfold and Ear PlugsBlindfolding and Noise CancellingPatient with sickle cell disease experiencing acute vaso-occlusive crisis randomized to this arm will wear a blindfold and ear plugs. The patient will be able to remain blindfolded and earplugs for a maximum of two hours.
Passive Immersive Virtual RealityVirtual Reality Headset and Hand-Held ControllersPatient with sickle cell disease experiencing acute vaso-occlusive crisis randomized to this arm will participate in a passive immersive application on the virtual reality headset with hand-held controllers. The passive immersive application will not allow the user to interact directly with the application or move through the virtual environment .The patient will be able to use the passive immersive application on the device for a maximum of two hours.
Primary Outcome Measures
NameTimeMethod
Comparison of the change in pain scores between the 3 groups at one hour after completion of the study intervention.A single time point 1 hour after the study intervention ends.

Patient reported on 0-10 scale

Secondary Outcome Measures
NameTimeMethod
Comparison of the proportion of subjects within each group who are hospitalized.Day of enrollment

Determine whether the patient is discharged home vs. placed in observation/admission status after completion of emergency department care.

Compare the total duration of Emergency Department treatment measured from the time of delivery of the first intervention to the time of disposition.Day of enrollment

Measured in hours/minutes

Comparison of the subject's assessment of comfort of the study intervention between the 3 groupsImmediately before intervention, at 1-hour mark of the intervention, immediately following the intervention, and 1 hour after the intervention ends.

Patient reported on 1-5 Likert scale

Comparison of the quantity opioids, converted to morphine milligram equivalents, administered while under the care of the ED clinical team.Day of enrollment

Measured in morphine milligram equivalents

Comparison of the change in pain scores between the 3 groups at one hour after study intervention begins.A single time point 1 hour after the study intervention begins.

Patient reported on 0-10 scale

Comparison of the change in pain scores between the 3 groups at completion of the study intervention.A single time point at the completion of the study intervention.

Patient reported on 0-10 scale

Trial Locations

Locations (1)

University of Maryland Medical Systems

🇺🇸

Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath